MNKD to Hold 2019 2Q Financial Results Conf Call on Aug 7

[kite]

WESTLAKE VILLAGE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 7, 2019.

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

To participate in the live call by telephone, please dial [phone] or [phone] and use the participant passcode: 8241782. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com under News & Events.

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing [phone] or [phone] and use the participant passcode: 8241782. A replay will also be available on MannKind's website for 14 days.


About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
Rose Alinaya
Investor Relations
818-661-5000
[e-mail]

[brianrocco]

I am hopeful, but not optimistic, that M. Castagna will discuss:
* retention rates for new Afrezza users;
* the issues raised by Vdex on why retention rates are generally so low;
* how effective protocols for use of Afrezza are going to be impressed upon endocrinologists and doctors if Mannkind and its salesmen cannot promote them because of FDA regulations;
* and perhaps even why Mannkind will not support Vdex by selling directly to them.

Doubling the retention rate to a reasonable, and not exceptional c. 50%, would significantly raise the slope of the revenue curve and reduce the time to Afrezza breakeven.

[prcgorman2]

Aug 1, 2019 16:04:29 GMT -5 kite said:

WESTLAKE VILLAGE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 7, 2019.

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

To participate in the live call by telephone, please dial [phone] or [phone] and use the participant passcode: 8241782. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com under News & Events.

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing [phone] or [phone] and use the participant passcode: 8241782. A replay will also be available on MannKind's website for 14 days.


About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
Rose Alinaya
Investor Relations
818-661-5000
[e-mail]

Middle of the week.  Does the timing mean anything?

[cretin11]

mytakeonit has predicted major news from this CC, if that comes true then perhaps we may deduce the unusual mid-week scheduling was a tell...

[awesomo]

Aug 2, 2019 9:33:19 GMT -5 prcgorman2 said:

Middle of the week.  Does the timing mean anything?

Never has before, doesn't matter what day of the week, before or after market. I wouldn't expect anything different this time.

[goyocafe]

Middle of the week. Does the timing mean anything?

Read more: mnkd.proboards.com/thread/11398/mnkd-hold-2019-financial-results?page=1#ixzz5vSMRdWKf

I think they’re at the end of the reporting window allowed by the SEC.

[theshiv]

The timing doesn't matter, the news does.
It is beyond obvious that a large infusion cash is needed to move the company forward.

[prcgorman2]

Aug 2, 2019 10:04:46 GMT -5 goyocafe said:

Middle of the week. Does the timing mean anything?

Read more: mnkd.proboards.com/thread/11398/mnkd-hold-2019-financial-results?page=1#ixzz5vSMRdWKf

I think they’re at the end of the reporting window allowed by the SEC.

From Investopedia:

The old standard required companies to file earnings reports no later than 45 days after the end of their first three quarters, and both quarterly and annual reports no more than 90 days after their fiscal year ends.

In 2002, the SEC decided to make information available to the public in a more timely manner. The new rules tightened these 45- and 90-day requirements to 35 and 60 days, respectively.

---

I think that means MNKD could provide a 2nd quarter earnings report as late as the end of August.

But my question was whether middle-of-the-week signals anything as compared to beginning or end of the week.  My sense is similar to awesomo's in that it probably does not matter.

[mytakeonit]

Makes sense to me ... because it's HUMP DAY !!! Also, people will always grumble when you choose any other day. "OH WHY does it have to be on Monday?!!!" "OH WHY does it have to be on Friday?!!!" What a bunch of cry babies !

But, that's mytakeonit

[hellodolly]

I've held off on buying, just in case they make an AH or pre-market announcement of additional dilution. I'm not saying that I'd like to get my shares under a buck but hey, if they do announce it around this quarterly call, I want to be ready.

[cretin11]

Aug 2, 2019 14:30:18 GMT -5 hellodolly said:

I've held off on buying, just in case they make an AH or pre-market announcement of additional dilution. I'm not saying that I'd like to get my shares under a buck but hey, if they do announce it around this quarterly call, I want to be ready.

Spoken like a MNKD shareholder who's been around for a while and has learned from the past.

[myocat]

Personally, I like good QTR call on Monday so that the momentum carries on the entire week. on the other hand, a bad one is on Friday with the weekend to soak in.

I hope, MNKD will announce a first shipment to Brazil.

[ktim]

Aug 2, 2019 8:59:21 GMT -5 brianrocco said:

I am hopeful, but not optimistic, that M. Castagna will discuss:
* retention rates for new Afrezza users;
* the issues raised by Vdex on why retention rates are generally so low;
* how effective protocols for use of Afrezza are going to be impressed upon endocrinologists and doctors if Mannkind and its salesmen cannot promote them because of FDA regulations;
* and perhaps even why Mannkind will not support Vdex by selling directly to them.

Doubling the retention rate to a reasonable, and not exceptional c. 50%, would significantly raise the slope of the revenue curve and reduce the time to Afrezza breakeven.

I am hoping (not the same as hopeful) that MC will present and discuss a more meaningful metric of the base of Afrezza "writers".  Looking at the current numbers it appears that writing a single script in 3 months gets a doc counted as an Afrezza doc.

[wgreystone]

Let's see if MC will expect scripts to rise again in 3 months with this new outdoor ad campaign.

[mnholdem]

Aug 2, 2019 15:26:34 GMT -5 myocat said:

Personally, I like good QTR call on Monday so that the momentum carries on the entire week. on the other hand, a bad one is on Friday with the weekend to soak in.

I hope, MNKD will announce a first shipment to Brazil.

i believe that’s a good possibility.